Merck’s Solid Quarter Doesn’t Soothe Seagen M&A Watchers
No Deal Was Announced, To The Chagrin Of Investors
Keytruda- and Gardasil-driven revenue growth exceeded forecasts and Merck expects to keep the PD-1 blockbuster cash coming with earlier-stage indications and a potential subcutaneous formulation.
You may also be interested in...
MSD India Chief On The Now, Next For Januvia, Gardasil And Keytruda’s Ascent
MSD India managing director Rehan Khan talks to Scrip about price adjustments for Januvia and the brand’s strong physician recall amid a tsunami of competition post loss of exclusivity, as also plans for Gardasil, which faces upcoming competition from Indian vaccines star Serum Institute. He also signals huge strides made by Keytruda, now the top cancer therapy in the country.
US Pharmas Display Defensive Mettle But Headwinds Mount
US big pharma manufacturers generally delivered sales and earnings growth in the second quarter and reaffirmed guidance despite currency headwinds; US drug pricing legislation could present a tipping pressure point.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: planned US drug pricing legislation in focus; solid quarter but no Seagen announcement for Merck & Co; AbbVie’s Gonzalez sounds alarm over US pricing legislation; Alnylam ready to expand in amyloidosis; and Boehringer Ingelheim on global Jardiance strategy.